<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2020-12-54-59</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-5865</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЗАБОЛЕВАНИЯ КОЖИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DERMAL DISEASES</subject></subj-group></article-categories><title-group><article-title>Эффективность и безопасность местной терапии атопического дерматита у детей дошкольного и школьного возраста</article-title><trans-title-group xml:lang="en"><trans-title>The efficacy and safety of local therapy of atopic dermatitis in infants and school-age children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1000-0664</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сидорович</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Sidorovich</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сидорович Ольга Игоревна – кандидат медицинских наук, старший научный сотрудник научно-консультативного отделения.115522, Москва, Каширское шоссе, д. 24.SPIN: 9757-8172</p></bio><bio xml:lang="en"><p>Olga I. Sidorovich - Cand. of Sci. (Med.), Lead Researcher of the Scientific Advisory Department, National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia.24, Kashirskoye Shosse, Moscow, 115478.</p></bio><email xlink:type="simple">dr.sidorovich@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3523-9372</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цывкина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsyvkina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цывкина Анастасия Александровна - кандидат медицинских наук, врач аллерголог-иммунолог.115522, Москва, Каширское шоссе, д. 24.</p></bio><bio xml:lang="en"><p>Anastasiya A. Tsyvkina - Cand. of Sci. (Med.), Allergist-Immunologist, National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia.24, Kashirskoye Shosse, Moscow, 115478.</p></bio><email xlink:type="simple">tsnastia@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0991-4346</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдуллаева</surname><given-names>Г. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Abdullaeva</surname><given-names>G. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абдуллаева Гульноза Давлатовна - врач аллерголог-иммунолог.115409, Москва, Каширское шоссе, д. 74, корп. 1.</p></bio><bio xml:lang="en"><p>Gulnoza D. Abdullaeva - Allergist-Immunologist, Medkvadrat Medical Center.74, Bldg. 1, Kashirskoye Shosse, Moscow, 115409.</p></bio><email xlink:type="simple">gulabdullaeva@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научный центр «Институт иммунологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Center - Institute of Immunology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Медицинский центр «Медквадрат»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medkvadrat Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>14</day><month>11</month><year>2020</year></pub-date><volume>0</volume><issue>12</issue><fpage>54</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сидорович О.И., Цывкина А.А., Абдуллаева Г.Д., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Сидорович О.И., Цывкина А.А., Абдуллаева Г.Д.</copyright-holder><copyright-holder xml:lang="en">Sidorovich O.I., Tsyvkina A.A., Abdullaeva G.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/5865">https://www.med-sovet.pro/jour/article/view/5865</self-uri><abstract><p>Атопический дерматит - мультифакторное, генетически обусловленное воспалительное заболевание кожи, возникающее вследствие нарушения эпидермального барьера на фоне предрасположенности к IgE-опосредованной гиперчувствительности, характеризующееся зудом, хроническим рецидивирующим течением, возрастными особенностями локализации и морфологии очагов поражения и требующее длительного/постоянного лечения, которое основывается на постоянном использовании эмолентов, топических ингибиторов кальциневрина, топических глюкокортикоидов и гигиеническом уходе за кожей.В основе механизмов развития атопического дерматита в первую очередь лежит генетическая предрасположенность к аллергии, нарушение нормального развития врожденных и приобретенных факторов иммунной системы, а также влияние факторов окружающей среды и различных триггерных факторов, как аллергенных (пищевые, бытовые, эпидермальные, грибковые аллергены и т. д.), так и неаллергенных (табачный дым, поллютанты, психоэмоциональное напряжение, сопутствующие хронические и острые заболевания, преимущественно ОРВИ, и т. д.).Установлено, что характерной чертой атопического дерматита является нарушение функции эпидермального барьера, приводящее к чрезмерной трансэпидермальной потере воды, к повышению проницаемости эпидермиса, проникновению аллергенов и микробных агентов через кожу и в конечном итоге - к сенсибилизации к аллергенам и развитию на ней специфического аллергического воспаления и реализации «атопического марша» с последовательным развитием других атопических заболеваний.Современные терапевтические стратегии активно направлены на восстановление эпидермального барьера, профилактику сенсибилизации и развития атопического марша. В данной статье изложены особенности нарушения функции эпидермального барьера при атопическом дерматите, перечислены возможности его восстановления и предотвращения последующих обострений посредством использования местной терапии и эмолентов, а также представлены 3 клинических случая.</p></abstract><trans-abstract xml:lang="en"><p>Atopic dermatitis is a multifactorial genetic inflammatory skin disease associated with disturbances of skin barrier function affected by predisposition to IgE-mediated hypersensitivity, which is characterized by itching, chronic recurrent course of the disease, age-related features of localization and lesion morphology, and requires the long-term and permanent treatment.Treatment is based on the continuous use of emollients, topical calcineurin inhibitors, topical glucocorticoids, and hygienic skin care.The mechanisms of the atopic dermatitis development are primarily based on a genetic predisposition to allergies, failure of the normal development of congenital and acquired factors of the immune system, as well as the influence of environmental factors and various trigger factors, such as allergenic (food, indoor, epidermal, fungal allergens, etc.). and non-allergenic (tobacco smoke, pollutants, psycho-emotional stress, concomitant chronic and acute diseases, mainly ARVI, etc.).It has been established that atopic dermatitis is characterized by the epidermal barrier dysfunction leading to excessive tran-sepidermal water loss, increased permeability of the epidermis, the penetration of allergens and microbial agents via the skin and eventually to sensitization to allergens and the development of specific allergic skin inflammation and atopic march with the sequential development of other atopic diseases.Modern therapeutic strategies are actively aimed at repairing the epidermal barrier, preventing sensitization and atopic march development. This article describes the features of the epidermal barrier dysfunction in atopic dermatitis, lists the methods of its restoration and ways to prevent subsequent exacerbations using local therapy and emollients, and presents 3 clinical cases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>экзема</kwd><kwd>ксероз</kwd><kwd>кожный зуд</kwd><kwd>местная терапия</kwd><kwd>эмоленты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>eczema</kwd><kwd>xerosis</kwd><kwd>pruritus</kwd><kwd>local therapy</kwd><kwd>emollients</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chatenoud L., Bertuccio P., Turati F., Galeone C., Naldi L., Chatenoud L. et al. Markers of microbial exposure lower the incidence of atopic dermatitis. Allergy. 2020;75(1):104-115. doi: 10.1111/all.13990.</mixed-citation><mixed-citation xml:lang="en">Chatenoud L., Bertuccio P., Turati F., Galeone C., Naldi L., Chatenoud L. et al. Markers of microbial exposure lower the incidence of atopic dermatitis. Allergy. 2020;75(1):104-115. doi: 10.1111/all.13990.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Vinding G.R., Esmann S., Jemec G.B. Quality of life in atopic dermatitis: changes over 6 years in patients who report persistent eczema. J Dermatol. 2012;39(8):721-722. doi: 10.1111/j.1346-8138.2012.01512.x.</mixed-citation><mixed-citation xml:lang="en">Vinding G.R., Esmann S., Jemec G.B. Quality of life in atopic dermatitis: changes over 6 years in patients who report persistent eczema. J Dermatol. 2012;39(8):721-722. doi: 10.1111/j.1346-8138.2012.01512.x.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Хаитов Р.М., Ильина Н.И. Аллергология и клиническая иммунология: клинические рекомендации. М.: ГЭОТАР-Медиа; 2019. 352 с.</mixed-citation><mixed-citation xml:lang="en">Khaitov R.M., Ilina N.I. Allergology and clinical immunology: clinical guidelines. Moscow: GEOTAR-Media; 2019. 352 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Draelos Z.D. Clinical situations conducive to proactive skin health and anti-aging improvement. J Investig Dermatol Symp Proc. 2008;13(1):25-27. doi: 10.1038/jidsymp.2008.9.</mixed-citation><mixed-citation xml:lang="en">Draelos Z.D. Clinical situations conducive to proactive skin health and anti-aging improvement. J Investig Dermatol Symp Proc. 2008;13(1):25-27. doi: 10.1038/jidsymp.2008.9.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brown S.J., McLean W.H. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3):751-762. doi: 10.1038/jid.2011.393.</mixed-citation><mixed-citation xml:lang="en">Brown S.J., McLean W.H. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132(3):751-762. doi: 10.1038/jid.2011.393.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi T., Glatz M., Horiuchi K., Kawasaki H., Akiyama H., Kaplan D.H. et al. Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity. 2015;42(4):756-766. doi: 10.1016/j.immuni.2015.03.014.</mixed-citation><mixed-citation xml:lang="en">Kobayashi T., Glatz M., Horiuchi K., Kawasaki H., Akiyama H., Kaplan D.H. et al. Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity. 2015;42(4):756-766. doi: 10.1016/j.immuni.2015.03.014.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Flores G.E., Seite S., Henley J.B., Martin R., Zelenkova H., Aguilar L., Fierer N. Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment. J Drugs Dermatol. 2014;13(11):1365-1372. Available at: https://pubmed.ncbi.nlm.nih.gov/25607704/.</mixed-citation><mixed-citation xml:lang="en">Flores G.E., Seite S., Henley J.B., Martin R., Zelenkova H., Aguilar L., Fierer N. Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment. J Drugs Dermatol. 2014;13(11):1365-1372. Available at: https://pubmed.ncbi.nlm.nih.gov/25607704/.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Williams M.R., Gallo R.L. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015;15(11):65. doi: 10.1007/s11882-015-0567-4.</mixed-citation><mixed-citation xml:lang="en">Williams M.R., Gallo R.L. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015;15(11):65. doi: 10.1007/s11882-015-0567-4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kennedy E.A., Connolly J., Hourihane J.O., Fallon P.G., McLean W.H.I., Murray D. et al. Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J Allergy ClinImmunol. 2017;139(1):166-172. doi: 10.1016/j.jaci.2016.07.029.</mixed-citation><mixed-citation xml:lang="en">Kennedy E.A., Connolly J., Hourihane J.O., Fallon P.G., McLean W.H.I., Murray D. et al. Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J Allergy ClinImmunol. 2017;139(1):166-172. doi: 10.1016/j.jaci.2016.07.029.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J., Kim B.E., Ahn K., Leung D.Y.M. Interactions Between Atopic Dermatitis and Staphylococcus aureus Infection: Clinical Implications. Allergy Asthma Immunol Res. 2019;11(5):593-603. doi: 10.4168/aair.2019.11.5.593.</mixed-citation><mixed-citation xml:lang="en">Kim J., Kim B.E., Ahn K., Leung D.Y.M. Interactions Between Atopic Dermatitis and Staphylococcus aureus Infection: Clinical Implications. Allergy Asthma Immunol Res. 2019;11(5):593-603. doi: 10.4168/aair.2019.11.5.593.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
